Kazia Therapeutics Limited Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
9Kazia rapeutics's Business Model
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
About Kazia rapeutics
Website: https://www.kaziatherapeutics.com
CEO (Chief Executive Officer): Dr. John Edwin Friend II, M.D.
IPO date: 1999-01-06
Contact
Country: AU
Address: Three International Towers
City: Sydney
State: NSW
Phone: 1300 787 272
Zip Code: 2000
Other
CIK: 0001075880
ISIN: US48669G1058
CUSIP: 48669G105
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
